CIBC Asset Management Inc Has $39.48 Million Holdings in Pfizer Inc. $PFE

Key Points

• CIBC Asset Management increased its Pfizer stake by 49.5% in the fourth quarter, adding 525,025 shares and bringing its total holdings to 1,585,657 shares worth about $39.48 million.
• Pfizer’s latest earnings beat expectations, posting $0.75 EPS versus the $0.72 consensus and revenue of $14.45 billion versus $13.84 billion expected, while reaffirming FY 2026 guidance of $2.80 to $3.00 EPS.
• The company also declared a quarterly dividend of $0.43 per share, equivalent to an annualized yield of about 6.8%, while analysts currently have an overall Hold rating with a consensus target price of $28.82.

CIBC Asset Management Inc raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 49.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,585,657 shares of the biopharmaceutical company's stock after buying an additional 525,025 shares during the quarter. CIBC Asset Management Inc's holdings in Pfizer were worth $39,483,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Kepler Cheuvreux Suisse SA acquired a new position in shares of Pfizer in the third quarter valued at $16,613,000. Penn Davis Mcfarland Inc. grew its position in Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock valued at $4,266,000 after acquiring an additional 57,777 shares during the period. Mackenzie Financial Corp grew its position in Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company's stock valued at $79,157,000 after acquiring an additional 1,691,773 shares during the period. Pzena Investment Management LLC grew its position in Pfizer by 0.9% in the third quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company's stock valued at $168,565,000 after acquiring an additional 56,484 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after acquiring an additional 5,978,927 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $25.37 on Thursday. The stock's fifty day moving average is $26.68 and its 200-day moving average is $26.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market capitalization of $144.57 billion, a PE ratio of 19.36 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.08 and a 52 week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio (DPR) is currently 131.30%.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Daiwa Securities Group cut Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Morgan Stanley upped their price target on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Pfizer in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology pipeline drew renewed optimism after ASCO 2026 data showed encouraging Phase 3 results for BRAFTOVI in metastatic colorectal cancer and TALZENNA in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Jefferies reiterated a buy rating on Pfizer, and another report highlighted Pfizer as undervalued, which may help support sentiment around the stock’s current valuation. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Pfizer also received coverage suggesting its obesity and oncology pipeline could deliver multiple catalysts in 2026, keeping investors focused on upcoming data readouts and regulatory events. Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, but the transcript appears to be mainly a routine investor update rather than a major new announcement. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Pfizer also announced updates on its ODEN ulcerative colitis study and completed a bevacizumab biosimilar safety study in Japan, both of which are incremental pipeline updates rather than immediate stock-moving breakthroughs. Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis
• Negative Sentiment: Some articles continue to frame Pfizer as a high-yield stock facing patent-cliff concerns and competitive comparisons with peers like Bristol Myers and Merck, which may weigh on sentiment despite the company’s pipeline progress. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.